Scholarlink

Background <p>Polymyxin B (PMB) is a polypeptide antibiotic primarily used to treat infections caused by multidrug-resistant gram-negative bacteria. Its main adverse effects are neurotoxicity and nephrotoxicity. Neurotoxicity may manifest as irritability, fatigue, lethargy, ataxia, dysgeusia, limb numbness, and blurred vision. Hearing impairment attributed to PMB is rarely reported. Herein, we describe a case of hearing impairment in a patient with renal dysfunction, potentially related to intravenous PMB therapy.</p> Case presentation <p>A 54-year-old, 70-kg male with poorly controlled type 2 diabetes (complicated by nephropathy, neuropathy, retinopathy), end-stage kidney disease (on hemodialysis), and hypertension was admitted to the ICU for gastrointestinal bleeding and hemorrhagic shock. On postoperative day 7, he developed carbapenem-resistant Acinetobacter baumannii (CR-AB) pneumonia and was treated with PMB 50&#xa0;mg q12h plus sulbactam 2&#xa0;g q8h. Therapeutic drug monitoring (TDM) showed the area under the plasma concentration-time curve across 24&#xa0;h at steady state (AUC<sub>ss, 24&#xa0;h</sub>) of PMB was 37.7&#xa0;mg·h/L. PMB was increased to 100&#xa0;mg q12h, after which the patient reported hearing impairment, with a corresponding AUC<sub>ss, 24&#xa0;h</sub> of 152.8&#xa0;mg·h/L. The dose was then reduced and subsequently discontinued. The patient’s hearing fully recovered one day after discontinuation. No formal audiologic testing was performed; the diagnosis relied on patient self-report and clinical observation.</p> Conclusions <p>This case highlights the importance of recognizing neurotoxic events related to PMB, including hearing impairment. Close monitoring and timely intervention are especially critical in patients with renal insufficiency or those receiving high-dose PMB. Accordingly, TDM plays an important role in anticipating and avoiding such adverse reactions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Polymyxin B-associated hearing impairment in a patient with renal dysfunction- a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月15日

查看全文
  • Xun Ni,
  • Tingting Ding,
  • Dandan Gong,
  • Xiaojuan Liu,
  • Jinna Wang,
  • Huanhuan Wu,
  • Xu Wang

摘要

Background

Polymyxin B (PMB) is a polypeptide antibiotic primarily used to treat infections caused by multidrug-resistant gram-negative bacteria. Its main adverse effects are neurotoxicity and nephrotoxicity. Neurotoxicity may manifest as irritability, fatigue, lethargy, ataxia, dysgeusia, limb numbness, and blurred vision. Hearing impairment attributed to PMB is rarely reported. Herein, we describe a case of hearing impairment in a patient with renal dysfunction, potentially related to intravenous PMB therapy.

Case presentation

A 54-year-old, 70-kg male with poorly controlled type 2 diabetes (complicated by nephropathy, neuropathy, retinopathy), end-stage kidney disease (on hemodialysis), and hypertension was admitted to the ICU for gastrointestinal bleeding and hemorrhagic shock. On postoperative day 7, he developed carbapenem-resistant Acinetobacter baumannii (CR-AB) pneumonia and was treated with PMB 50 mg q12h plus sulbactam 2 g q8h. Therapeutic drug monitoring (TDM) showed the area under the plasma concentration-time curve across 24 h at steady state (AUCss, 24 h) of PMB was 37.7 mg·h/L. PMB was increased to 100 mg q12h, after which the patient reported hearing impairment, with a corresponding AUCss, 24 h of 152.8 mg·h/L. The dose was then reduced and subsequently discontinued. The patient’s hearing fully recovered one day after discontinuation. No formal audiologic testing was performed; the diagnosis relied on patient self-report and clinical observation.

Conclusions

This case highlights the importance of recognizing neurotoxic events related to PMB, including hearing impairment. Close monitoring and timely intervention are especially critical in patients with renal insufficiency or those receiving high-dose PMB. Accordingly, TDM plays an important role in anticipating and avoiding such adverse reactions.